FDA Requires New Safety Warnings for GLP-1 Drugs
The U.S. Food and Drug Administration (FDA) is warning patients and healthcare providers that GLP-1 medications are associated with an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can result in permanent vision loss.
“Symptoms of NAION include sudden, painless vision loss in one eye upon waking; blurred or missing portions of vision (visual defects such as blind spots or tunnel vision); distortion of colors; and reduced central sharpness (e.g., blurry or hazy spots),” the FDA warned in a new drug safety communication. “Patients should contact their healthcare professional right away if they experience any of these symptoms.”
This new warning from the FDA comes after the agency reviewed years of data on GLP-1 drugs and the risk of NAION, even performing a retrospective study.
Overall, after examining over 100 randomized clinical trials covering a wide range of GLP-1 medications, the FDA found that there were 6.4 NAION cases per 100,000 person-years in patients treated with GLP-1 drugs, compared to 3.8 NAION cases per 100,000 person-years for patients on a placebo or another glucose-lowering medication. NAION cases were reported for “all currently marketed GLP-1 receptor agonist products.”
Reviewing these data, the FDA concluded that there is “a potential increased risk of rare NAION events in patients taking GLP-1 receptor agonists.” This risk appears to be higher in patients with a history of NAION.
As a result, warnings about this risk are now required to be included in the labeling of these medications.
GLP-1s are one of healthcare’s largest trends. GLP-1 receptor agonists, including popular drugs like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), have been a significant trend in modern medicine. Originally developed to treat diabetes, they are now primarily prescribed for weight loss, and multiple GLP-1 medications have demonstrated cardiovascular benefits, increasing their popularity among cardiologists. However, as quickly as these drugs were embraced, concerns have arisen about potential, as yet unidentified, side effects.